MK 1966

Drug Profile

MK 1966

Alternative Names: MK-1966

Latest Information Update: 02 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck & Co
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Immunomodulators; Interleukin 10 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies

Most Recent Events

  • 08 Jan 2018 Merck terminates phase I trial in Haematological malignancies (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intratumoural) (NCT02731742)
  • 01 Jun 2016 Phase-I clinical trials in Haematological malignancies (Combination therapy; Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02731742)
  • 01 Jun 2015 Dynavax Technologies and Merck agree to co-develop SD 101 and MK 1966 for Haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top